Reviving old antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2177-2181

  Theuretzbacher, Ursula ^a   Van Bambeke, Françoise ^b   Cantón, Rafael ^c   Giske, Christian G ^d,e   Mouton, Johan W ^f,g   Nation, Roger L ^h   Paul, Mical ⁱ   Turnidge, John D ^j   Kahlmeter, Gunnar ^k,l  

^a Center For Anti Infective Agents Vienna   (Austria)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^h MONASH UNIVERSITY   (Australia)

ⁱ TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^j UNIVERSITY OF ADELAIDE   (Australia)

^k CENTRAL HOSPITAL   (Sweden)

^l UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COMMUNITY ACQUIRED INFECTION; DISEASE SEVERITY; DRUG LEGISLATION; DRUG REPOSITIONING; DRUG USE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FUNDING; HEALTH CARE ACCESS; HOSPITAL INFECTION; HUMAN; KNOWLEDGE; MULTICENTER STUDY (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); BACTERIAL INFECTIONS; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; STANDARDS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS;

EID: 84939559053     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv157     Document Type: Article

References (35)

1. Cassir N, Rolain J-M, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014; 5: 551.
2. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 2015; 277: 501-12.
3. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
4. Pitout JD. Enterobacteriaceae that produce extended-spectrum β-lactamases and AmpC β-lactamases in the community: the tip of the iceberg? Curr Pharm Des 2013; 19: 257-63.
5. Keating G. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 2013; 73: 1951-66.
6. Tasbakan MI, Pullukcu H, Sipahi OR et al. Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents 2012; 40: 554-6.
7. Titelman E, Iversen A, Kalin M et al. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2011; 18: 189-92.
8. Livermore DM, Warner M, Mushtaq S et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-9.
9. Michalopoulos A, Virtzili S, Rafailidis P et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16: 184-6.
10. Livermore DM, Tulkens PM. Temocillin revived. Antimicrob Chemother 2009; 63: 243-5.
11. Tambyah PA, Hara GL, Daikos GL et al. Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. J Global Antimicrob Res 2013; 1: 117-22.
12. Nation RL, Li J, Cars O et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015; 15: 225-34.
13. Mouton JW, Ambrose PG, Canton R et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Update 2011; 14: 107-17.
14. European Commission 2011. AIDA-Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic/pharmacodynamic approach to optimize effectiveness and reduce resistance for offpatent antibiotics. Community Research and Development information Service. http://cordis.europa.eu/project/rcn/101361_en.html.
15. NIH News 2010. National Institutes of Health. NIH funds four clinical trials to fight antimicrobial resistance. http://www.nih.gov/news/health/oct2010/niaid-19.htm.
16. Landersdorfer CB, Nation RL. Colistin: how should it be dosed for the critically ill? Semin Respir Crit Care Med 2015; 36: 126-35.
17. Bergen PJ, Bulman ZP, Saju S et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 2015; 35: 34-42.
18. Theuretzbacher U. Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 2014; 69: 1987-92.
19. European Medicines Agency. EMA/643444/2014. Review of polymyxinbased medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/10/WC500176334.pdf.
20. European Medicines Agency. EMA/MB/151414/2015. EU Medicines Agencies Network Strategy to 2020. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/03/WC500185138.pdf.
21. Monaco M, Giani T, Raffone M et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill 2014; 19: pii:20939.
22. Ah YM, Kim AJ, Lee JY. Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents 2014; 44: 8-15.
23. Qureshi ZA, Hittle LE, O'Hara JA et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015; 60: 1295-303.
24. Pulcini C, Bush K, Craig WA et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012; 54: 268-74.
25. Quadri F, Mazer-Amirshahi M, Fox ER et al. Antibacterial drug shortages from 2001 to 2013: implications for clinical practice. Clin Infect Dis 2015; 60: 1737-42.
26. Council of the European Union. Brussels 2009. Council conclusions on innovative incentives for effective antibiotics. http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/111608.pdf.
27. Nathan C, Cars O. Antibiotic resistance-problems, progress, and prospects. N Engl J Med 2014; 371: 1761-3.
28. Laxminarayan R, Duse A, Wattal C et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013; 13: 1057-98.
29. Stansly PG, Shepherd RG, White HJ. Polymyxin: a new chemotherapeutic agent. Bull Johns Hopkins Hosp 1947; 81: 43-54.
30. Anonymous. Chloromycetin, a new microbiotic agent. Am Prof Pharm 1947; 13: 1105.
31. Anonymous. New and nonofficial remedies: nitrofurantoin. J Am Med Assoc 1954; 154: 339.
32. Redin GS. Antibacterial activity in mice of minocycline, a new tetracycline. Antimicrob Agents Chemother 1966; 6: 371-6.
33. Hendlin DSE, Jackson M, Wallick H et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969; 166: 122-3.
34. Reeves DS, Wise R, Bywater MJ. A laboratory evaluation of a novel β-lactam antibiotic mecillinam. J Antimicrob Chemother 1975; 1: 337-44.
35. Slocombe B, Basker MJ, Bentley PH et al. BRL 17421, a novel β-lactam antibiotic, highly resistant to β-lactamases, giving high and prolonged serum levels in humans. Antimicrob Agents Chemother 1981; 20: 38-46.